Tscan Therapeutics is trading 5.42% down now at $0.78 as broader risk-off pressure weighs on growth-oriented stocks.
- No new company-specific announcement, filing, analyst action, or clinical catalyst was identified for August 19, 2026.
- Elevated Treasury yields and the previous session’s technology-led selloff appear to be weighing on biotechnology and other growth stocks.
- The latest material company update was the August 12, 2026, quarterly report.